New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis

Minerva Cardioangiologica

Volumn 53, Issue 5, 2005, Pages 341-360

  Vaina, S ^a   Ong, A T L ^a   Serruys, P W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angioplasty, transluminal coronary; Coronary disease; Stents

Indexed keywords

ABT 578; ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBOCYTIC AGENT; AVI 4126; BIOLIMUS A 9; DEXAMETHASONE; ESTRADIOL; EVEROLIMUS; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METAL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PACLITAXEL; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SIMVASTATIN; TACROLIMUS; TITANIUM; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; GRAFT REJECTION; HEART DISEASE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; THROMBOSIS;

CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; SIROLIMUS; STENTS; TREATMENT FAILURE;

EID: 28444439615     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Moses JW, Leon MB, Popina JJ, Fitzgerald FJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
2. Stone GW, ElHs SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109: 1942-7.
3. Meredith I. Endeavor DES Program. Endeavor I-IV summary update. In: TCT2004; 2004. Washington, USA; 2004.
4. Chevalier B. ZoMaxx: global and clinical programme development. In: Euro PCR 2005; 2005; Paris, France; 2005.
5. Meredith IT, Ormiston J, Whitbourn R, Kay P, Muller D, Popma JJ et al. ENDEAVOR I "first-in-human" safety and efficacy study. 12-month clinical, angiographic, and intravascular ultrasound results. Circulation 2004;110:III-563-III-564.
6. Wijns W, Fajadet J, Kuntz RE. A randomized comparison of the endeavor ABT-578 drug Eluting Stent With a Bare Metal Stent for Coronary Revascularization: Results of the Endeavor II Trial. 54th ACC Annual Scientific Session, 2005, March 6-9, Orlando, USA.
7. Grube E. FUTURE Clinical Trials. Champion TM Everolimus Eluting Coronary Stent System. In: TCT2004; 2004; Washington, USA; 2004.
8. Serruys PW, Ong ATL, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Euro Intervention 2005;1:58-69.
9. Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005;95:113-6.
10. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71.
11. Grube E. FUTURE II: Multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent. In: TCT; 2003; Washington, USA; 2003.
12. Grube E, Hauptmann KE, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9(tm) eluting stent with a biodegradable polymer coating. EuroIntervention 2005;1:53-7.
13. Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000;2000:1-23.
14. Morice MC. JUPITER II Trial. Six-month interim clinical data. In: EuroPCR 2005; 2005; Paris, France; 2005.
15. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574-9.
16. Rubanyi GM, Johns A, Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol 2002;38:89-98.
17. Abizaid A, Albertal M, Costa MA, Abizaid AS, Staico R, Feres F et al. First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 2004;43:1118-21.
18. Liu X, Huang Y, Hanet C, Vandormael M, Legrand V, Dens J et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003;60:172-8; discussion 179.
19. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003;107:2274-9.
20. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001;49:281-7.
21. Tanabe K, Ishiyama H, van der Giessen W, Serruys PW. Terumo statin releasing stent (preclinical results). In: Serruys PW, Gershlick A, editors. Drug-Eluting Stents. London: Taylor and Francis Group; 2005. p. 313-21.
22. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000;35:214-21.
23. Kipshidze NN, Iversen P, Kim HS, Yiazdi H, Dangas G, Seaborn R et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv 2004;61:518-27.
24. Kipshidze N, Overlie P, Dunlap T, Titus B, Lee D, Lauer M. First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: Six-month clinical and angiographic follow-up from AVAIL study. In: American Heart Association, Scientific Sessions, 2004, November 7-10, New Orleans, USA.
25. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-60.
26. Aoki J, Ong ATL, Abizaid A, den Heijer P, Bonnier H, McClean DR et al. One-year clinical outcome of varicous doses and pharmakinetic release formulations of paclitaxel eluted from an erodable polymer-insight in the Paclitael in Stent Controlled Elution Study (PISCES). Euro Intervention 2005;2:165-72.
27. Kaul U. Erodablepolymer-reservoir Paclitaxeldrug eluting stents II: Cobalt chromium platforms in complex lesions. In: TCT; 2004; Washington, USA; 2004.
28. Serruys PW. The new CoStar TM stent: 12 month results with the new DES technology. In: EuroPCR 2005; 2005; Paris, France; 2005.
29. Dawkins K. The Eurostar trial. In: EuroPCR 2005; 2005; Paris, France; 2005.
30. Gambhir DS. The Infinnium polymere-based paclitaxel drug-eluting stent: Results from real world clinical trials SIMPLE 1 and SIMPLE 2. In: TCT2004; 2004; Washington, USA; 2004.
31. Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001;104:928-33.
32. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 2005;111:26l7-22.
33. Mauri L, O'Malley AJ, Popma JJ, Moses JW, Leon MB, Holmes DR Jr et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2005;95:1140-5.
34. Tsagalou E, Chieffo A, Iakovou I, Ge L, Sangiorgi GM, Corvaja N et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005;45:1570-3.
35. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
36. Hoye A, van Mieghem CAG, Ong ATL, Aoki J, Rodriguez Granillo GA, Valgimigli M et al. Treatment of de novo bifurcation lesions: comparison of Sirolimus-and Paclitaxel-eluting stents. EuroIntervention 2005;1:24-30.
37. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109:1244-9.
38. Ormiston JA, Currie E, Webster MW, Kay P, Ruygrok PN, Stewart JT et al. Drug-eluting stents for coronary bifurcations: insights into the crush technique. Catheter Cardiovasc Interv 2004;63:332-6.
39. Ormiston JA, Webster MW, El Jack S, Ruygrok PN, Stewart JT, Scott D et al. Drug-eluting stents for coronary bifurcations: Bench testing of provisional side-branch s trategies. Catheter Cardiovasc Interv 2005 Jul 7; [Epub ahead of print]
40. Hoye A, van Mieghem CA, Ong AT, Aoki J, Rodriguez Granillo GA, Valgimigli M et al. Percutaneous therapy of bifurcation lesions with drug-eluting stent implantation: the Culotte technique revisited. Int J Cardiovasc Intervent 2005;7:36-40.
41. Ge L, Iakovou I, Cosgrave J, Agostoni P, Airoldi F, Sangiorgi GM et al. Treatment bifurcation lesions with two stents: crush versus T Stenting - one year angiographic and clinical follow-up. Heart 2005 Jun 17; [Epub ahead of print]
42. Eeckhout E, Berger A, Lyon X, Imsand C, Davin L, Meier JM et al. Elective ostial left main stenting: a tailored approach. J Invasive Cardiol 2005;17:125-8.
43. Agostoni P, Valgimigli M, Van Mieghem CA, Rodriguez-Granillo GA, Aoki J, Ong AT et al. Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance. Am J Cardiol 2005;95:644-7.
44. Wood F, Bazemore E, Schneider JE, Jobe RL, Mann T. Technique of left main stenting is dependent on lesion location and distal branch protection. Catheter Cardiovasc Interv 2005;65:499-503.
45. Chieffo A, Stankovic G, Bonizzoni E, Tsagalou E, Iakovou I, Montorfano M et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111:791-5.
46. Valgimigli M, van Mieghem CA, Ong AT, Aoki J, Granillo GA, McFadden EP et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005;111:1383-9.
47. Cheneau E, Rha SW, Kuchulakanti PK, Stabile E, Kinnaird T, Torguson R et al. Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Catheter Cardiovasc Interv 2005;65:469-72.
48. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704-8.
49. Hofma SH, Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M et al. One year clinical follow-up of paclitaxel-eluting stents for acute myocardial infarction compared to sirolimus-eluting stents. Heart 2005;91:1176-80.
50. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-17.
51. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
52. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-2.
53. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
54. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
55. Mauri L, Orav EJ, O'Malley AJ, Moses JW, Leon MB, Holmes DR Jr et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005;111:321-7.
56. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998;81(7A):14E-17E.
57. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499-506.
58. Lee MS, David EM, Makkar RR, Wilentz JR. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. J Pathol 2004;203:86l-70.
59. Holmes DRJr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-40.
60. Moussa I, Leon MB, Bairn DS, O'Neill WW, Popma JJ, Buchbinder M et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRoIImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8.
61. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5.
62. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-41.
63. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003;107:2178-80.
64. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-73.
65. Van Beusekom HMM, Saia F, Zindler JD, Lemos P, Leeuwen M, Serruys PW et al. Restenotic tissue obtained from sirolimus-eluting stents shows lower cell density and sings of incomplete woundhealing compared to restenodc tissue of hare metal stents. Eur Heart J 2004;26 Suppl:P3354.
66. Castagna MT, Mintz GS, Leihoff BO, Ahmed JM, Mehran R, Satler LF et al. The contribution of "mechanical" problems to in-stent restenosis: an intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J 2001;142:970-4.
67. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K et al. Coronary restenosis after sirolimuseluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003;108:257-60.
68. Schofer J, Schluter M. Coronary restenosis after implantation of drug-eluting stents. Minerva Cardioangiol 2005;53:43-8.
69. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ et al. Clinical, angiographic, and procedural predictors of angiographic, restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109:1366-70.
70. Zahn R, Hamm CW, Schneider S, Zeymer U, Nienaher CA, Richardt G et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter german cypher stent registry). Am J Cardiol 2005;95:1302-8.
71. Carter AJ. TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv 2004;61:233-6.
72. Lemos PA, van Mieghem CA, Arampatzis CA, Hoye A, Ong AT, McFadden E et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation 2004;109:2500-2.
73. van Beusekom HM, Whelan DM, Hofma SH, Krabbendarn SC, van Hinsbergh VW, Verdouw PD et al. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol 1998;32:1109-17.